Novartis to buy US-listed Avidity Biosciences for $12 bln

Novartis announced its intent to acquire U.S. biotech firm Avidity Biosciences for approximately $12 billion in cash, or $72 per share, representing a 46% premium to Avidity's Friday close. This strategic move aims to enhance Novartis's drug pipeline with Avidity's portfolio of treatments for rare, genetic muscle disorders, contingent on Avidity spinning off its precision cardiology programs. Expected to close in the first half of 2026, the acquisition underscores Novartis's ongoing M&A strategy to expand its therapeutic areas amid intense global competition.

Analysis

Novartis AG has announced its intention to acquire U.S. biotech firm Avidity Biosciences for approximately $12 billion in cash, offering $72 per share. This valuation represents a significant 46% premium over Avidity's Friday closing price, highlighting Novartis's strategic imperative to secure Avidity's specialized portfolio of treatments for rare, genetic muscle disorders. The deal is poised to significantly enhance Novartis's drug pipeline in a high-value therapeutic area.

This acquisition is consistent with Novartis's broader M&A strategy, which has seen the company invest nearly $6 billion this year across cardiovascular, renal, and neuromuscular therapeutic areas. The aggressive inorganic growth strategy aims to strengthen its competitive position and expand its therapeutic footprint in the face of intense global competition within the pharmaceutical industry.

The transaction is anticipated to conclude in the first half of 2026, subject to critical conditions including regulatory approval and Avidity successfully spinning off its early-stage precision cardiology programs into a new entity. The overall market sentiment appears moderately positive, suggesting investor confidence in the strategic rationale and potential long-term benefits of this pipeline expansion for Novartis.

Key Decisions for Investors

• Investors in Novartis should assess the strategic implications of this substantial $12 billion acquisition, considering its impact on the company's balance sheet, future R&D pipeline, and long-term growth trajectory in rare diseases.
• Shareholders of Avidity Biosciences should evaluate the attractive 46% premium offered and understand the mechanics and potential value of the planned spin-off of its precision cardiology programs prior to the deal's closure.
• All interested parties should closely monitor the progress of regulatory approvals and the successful execution of Avidity's cardiology spin-off, as these are critical contingencies for the transaction's completion in early 2026.